Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:35:09 2024-05-31 EDT			5-day change	1st Jan Change
1.23 ^USD	-1.60%		-0.16%	+10.17%

04-16	Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	MT
04-16	Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	MT

Arch Biopartners Appoints Adrian Haigh to Board of Directors as an Interim Director

August 21, 2014 at 08:21 am

Arch Biopartners Inc. announced the board has appointed Adrian Haigh as an interim director. Mr. Haigh is currently Senior Vice President, Commercial Operations and Chief Operating Officer of Gentium GmbH.

Latest news about Arch Biopartners Inc.

Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	04-16	MT
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-16	MT
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-16	CI
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide	04-03	MT
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	04-03	CI
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide	04-02	MT
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	04-02	CI
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation	03-18	MT
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2	03-18	CI
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI	03-15	MT
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	03-15	CI
Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide	03-07	MT
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	03-07	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	02-29	CI
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase Ii Cardiac Surgery Associated-Acute Kidney Injury Trial for Lsalt Peptide	02-29	CI
Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial	02-29	CI
Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-28	CI
Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury	02-27	MT
Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	01-28	CI
Arch Biopartners Inc.(TSXV:ARCH) added to S&P/TSX Venture Composite Index	01-22	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial For LSALT Peptide	01-10	MT
Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	01-10	CI
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide	01-03	MT
Arch Biopartners Inc. Receives Approval from the Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	01-03	CI
Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide	12-21	CI

Chart Arch Biopartners Inc.

Duration

Period

More charts

Company Profile

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.23

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCH BIOPARTNERS INC.	+10.17%	78.54M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research